Bevacizumab + RG1415 (erlotinib hydrochloride) combination therapy and the non-blind, randomized comparison to compare the RG1415 monotherapy Phase II clinical trials as a primary therapy for non-small-cell lung cancer patients with EGFR gene mutation

Trial Profile

Bevacizumab + RG1415 (erlotinib hydrochloride) combination therapy and the non-blind, randomized comparison to compare the RG1415 monotherapy Phase II clinical trials as a primary therapy for non-small-cell lung cancer patients with EGFR gene mutation

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2016

At a glance

  • Drugs Erlotinib (Primary) ; Bevacizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Chugai Pharmaceutical
  • Most Recent Events

    • 08 Jun 2016 Results published in a Roche media release.
    • 08 Jun 2016 According to a Roche media release, the European Commission has approved the use of Avastin (bevacizumab) in combination with Tarceva (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.
    • 29 Apr 2016 Results published in Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top